Antibodies of the invention produce such synergistic effects via allosteric and/or competitive inhibition of IGF-1R ligand binding.doi:CN101842117 AStephen DemarestKandasamy HariharanCNKandasamy, H.; Glaser, S.; Garber, E.; Graff, C.; Reyes, C.; Demarest, S. Anti-IGF-1R antibodies and ...
The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine mon
Anti-IGF-1R antibodies and uses thereof 专利名称：Anti-IGF-1R antibodies and uses thereof 发明人：STEPHEN DEMAREST,KANDASAMY HARIHARAN 申请号：AU2008295506 申请日：20080828 公开号：AU2008295506A1 公开日：20090312 专利内容由知识产权出版社提供 摘要：The invention relates to antibodies which bind to ...
The invention relates to antibodies which bind to insulin like growth factor receptor -1 (IGF-IR) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, an...
BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIESThe present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies.Brinkmann, UlrichCroasdale, Rebecca...
The insulin-like growth factor (IGF) signaling system plays a critical role in tumorigenesis, highlighting the potential of targeting IGF-1R as an anti-cancer therapy. Although multiple anti-IGF-1R monoclonal antibody (mAb) drugs have been developed, cha
Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patie
Anti-IGF-1R monoclonal antibodies have thus far shown limited success in clinical development (Jassem et al, 2010; Guha, 2013). This lack of significant antitumour activity has partly been attributed to the resistance (Pollak, 2012; Yee, 2012; Guha, 2013). The activation of the PI3K/AKT/...
Additionally, combination therapies of other treatments with CRAF/pan-RAF inhibitors, including RASG12C covalent inhibitors, EGFR inhibitors, MEK inhibitors, CDK inhibitors, Rb-CRAF inhibitors, PI3K inhibitors, STAT inhibitors, mTOR inhibitors, PD-1/PD-L1 antibodies, and CTLA-4 antibody are shown....
20130084243 IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS 2013-04-04 Goetsch et al. 20130041004 Liquid Formulations Of Bendamustine 2013-02-14 Drager et al. 20120315219 Drug Delivery Coating For Use With A Stent 2012-12-13 Labrecque et al. ...